Stock MRUS MERUS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Merus N.V. Stock

Equities

MRUS

NL0011606264

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
54.87 USD -8.53% Intraday chart for Merus N.V. +25.50% +99.53%
06:17pm Guggenheim Adjusts Merus Price Target to $93 From $57, Maintains Buy Rating MT
06:15pm BMO Capital Adjusts Merus Price Target to $84 From $58, Maintains Outperform Rating MT

Financials (USD)

Sales 2024 * 40.97M Sales 2025 * 53.57M Capitalization 3.52B
Net income 2024 * -177M Net income 2025 * -225M EV / Sales 2024 * 85.9 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 65.7 x
P/E ratio 2024 *
-20.2 x
P/E ratio 2025 *
-17.2 x
Employees 201
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.53%
More Fundamentals * Assessed data

Chart Merus N.V.

Dynamic Chart

Latest news about Merus N.V.

Guggenheim Adjusts Merus Price Target to $93 From $57, Maintains Buy Rating MT
BMO Capital Adjusts Merus Price Target to $84 From $58, Maintains Outperform Rating MT
Stifel Adjusts Price Target on Merus to $90 From $65, Maintains Buy Rating MT
Sector Update: Health Care Stocks Decline Late Friday Afternoon MT
Top Midday Gainers MT
Merus Rallies Ahead of Upcoming Presentations for Prospective Cancer Treatments, Price Target Boost at BoA Securities MT
BofA Adjusts Price Target on Merus to $61 From $52, Maintains Buy Rating MT
Top Premarket Gainers MT
Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab MT
Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation DJ
Merus N.V. Announces Petosemtamab Grants Breakthrough Therapy Designation by the U.S. FDA CI
Earnings Flash (MRUS) MERUS N.V. Posts Q1 Revenue $7.9M MT
Merus N.V. Appoints Jason Haddock as Non-Executive Director CI
Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says MT
Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target MT
More news

Analyst Recommendations on Merus N.V.

Guggenheim Adjusts Merus Price Target to $93 From $57, Maintains Buy Rating MT
BMO Capital Adjusts Merus Price Target to $84 From $58, Maintains Outperform Rating MT
Stifel Adjusts Price Target on Merus to $90 From $65, Maintains Buy Rating MT
BofA Adjusts Price Target on Merus to $61 From $52, Maintains Buy Rating MT
Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target MT
More recommendations

Press releases Merus N.V.

Merus N.V. Announces Proposed Public Offering of Common Shares GL
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC GL
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC AQ
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting GL
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting AQ
More press releases

News in other languages on Merus N.V.

GNW-Adhoc: Vorläufige Ergebnisse von Merus zu Petosemtamab in Kombination mit Pembrolizumab zeigen robuste Ansprechrate und günstiges Sicherheitsprofil bei Erstlinienbehandlung von rezidivierendem/metastasierendem HNSCC
Les données intermédiaires du pétosemtamab de Merus en association avec le pembrolizumab démontrent un taux de réponse important et un profil d’innocuité favorable dans le traitement de première ligne du CETC r/m
Vorläufige Ergebnisse von Merus zu Petosemtamab in Kombination mit Pembrolizumab zeigen robuste Ansprechrate und günstiges Sicherheitsprofil bei Erstlinienbehandlung von rezidivierendem/metastasierendem HNSCC
GNW-Adhoc: Merus kündigt Veröffentlichung eines Abstracts zu Petosemtamab mit Pembrolizumab als Erstlinienbehandlung von rezidivierenden/metastasierten Kopf- und Halstumoren der ASCO®-Jahrestagung 2024 an
Merus : publication d’un résumé sur l’association pétosemtamab + pembrolizumab dans le traitement de 1re ligne du CETC r/m lors de l’édition 2024 du congrès ASCO®
More news

Quotes and Performance

1 day-8.53%
1 week+25.50%
Current month+22.18%
1 month+21.64%
3 months+12.67%
6 months+128.43%
Current year+99.53%
More quotes

Highs and lows

1 week
43.33
Extreme 43.325
61.61
1 month
42.60
Extreme 42.6
61.61
Current year
27.11
Extreme 27.11
61.61
1 year
19.81
Extreme 19.805
61.61
3 years
12.03
Extreme 12.03
61.61
5 years
10.18
Extreme 10.18
61.61
10 years
7.26
Extreme 7.255
61.61
More quotes

Managers and Directors - Merus N.V.

Managers TitleAgeSince
Bill Lundberg CEO
 Chief Executive Officer 60 19-06-11
Gregory Perry DFI
 Director of Finance/CFO 63 16-04-30
Ernesto Wasserman CTO
 Chief Tech/Sci/R&D Officer - 16-11-30
Members of the board TitleAgeSince
Gregory Perry DFI
 Director of Finance/CFO 63 16-04-30
Maxine Gowen BRD
 Director/Board Member 66 21-05-27
Paolo Pucci BRD
 Director/Board Member 63 20-06-29
More insiders

ETFs positioned on Merus N.V.

Name Weight AuM 1st Jan change Investor Rating
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
0.11% 2 M€ -.--%
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
0.07% 0 M€ 0.00% -
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares 3x Long Biotechnology ETP Securities - USD
0.06% 0 M€ 0.00% -
BMO MSCI INNOVATION INDEX ETF - CAD ETF BMO MSCI Innovation Index ETF - CAD
0.04% 7 M€ -.--% -
More ETFs positioned on Merus N.V.

Quotes

Date Price Change Volume
24-05-28 54.87 -8.53% 3 857 025
24-05-24 59.99 +36.12% 6,908,179
24-05-23 44.07 +1.54% 1,613,248
24-05-22 43.4 -0.73% 472,778
24-05-21 43.72 +0.21% 901,846

Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT

More quotes

Company Profile

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Sector
Biotechnology & Medical Research
Calendar
08:00am - Business Update Call
More about the company

Income Statement Evolution

More financial data

Ratings for Merus N.V.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
59.99 USD
Average target price
73.36 USD
Spread / Average Target
+22.29%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MERUS N.V. Stock Merus N.V.
+99.53% 3.52B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.83% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.80% 106B
BIONTECH SE Stock BioNTech SE
-10.84% 23.4B
ARGENX SE Stock argenx SE
-1.69% 22.1B
GENMAB A/S Stock Genmab A/S
-10.23% 18.34B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.92% 16.59B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.11% 15.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.62% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+17.53% 11.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MRUS Stock